Suppr超能文献

新型冠状病毒变异株刺突蛋白突变及抗体研发的研究进展

Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development.

作者信息

Huan Xinkang, Zhan Jiuyu, Gao Hongwei

机构信息

School of Life Science, Ludong University, Yantai, Shandong, China.

出版信息

Front Immunol. 2024 Nov 18;15:1407149. doi: 10.3389/fimmu.2024.1407149. eCollection 2024.

Abstract

The coronavirus disease 2019 (COVID-19) is a respiratory disease with a very high infectious rate caused by the Severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2). Because SARS-CoV-2 is easy to mutate, the continuous emergence of SARS-CoV-2 variant strains not only enhances the infectivity of the SARS-CoV-2 but also brings great obstacles to the treatment of COVID-19. Neutralizing antibodies have achieved good results in the clinical application of the novel coronavirus pneumonia, which can be used for pre-infection protection and treatment of novel coronavirus patients. This review makes a detailed introduction to the mutation characteristics of SARS-CoV-2, focusing on the molecular mechanism of mutation affecting the infectivity of SARS-CoV-2, and the impact of mutation on monoclonal antibody therapy, providing scientific reference for the prevention of SARS-CoV-2 variant strains and the research and development of antibody drugs.

摘要

2019冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的一种具有很高感染率的呼吸道疾病。由于SARS-CoV-2易于变异,SARS-CoV-2变异株的不断出现不仅增强了SARS-CoV-2的传染性,也给COVID-19的治疗带来了巨大障碍。中和抗体在新型冠状病毒肺炎的临床应用中取得了良好效果,可用于新型冠状病毒感染前的预防及新型冠状病毒患者的治疗。本文详细介绍了SARS-CoV-2的突变特征,重点阐述了突变影响SARS-CoV-2传染性的分子机制以及突变对单克隆抗体治疗的影响,为预防SARS-CoV-2变异株及抗体药物研发提供科学参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/6cedd0b0f68a/fimmu-15-1407149-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验